HomeCompareAVTE vs ADC

AVTE vs ADC: Dividend Comparison 2026

AVTE yields 74.63% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVTE wins by $1.12M in total portfolio value
10 years
AVTE
AVTE
● Live price
74.63%
Share price
$2.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.30M
Annual income
$358,033.82
Full AVTE calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — AVTE vs ADC

📍 AVTE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVTEADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVTE + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVTE pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVTE
Annual income on $10K today (after 15% tax)
$6,343.28/yr
After 10yr DRIP, annual income (after tax)
$304,328.75/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, AVTE beats the other by $235,651.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVTE + ADC for your $10,000?

AVTE: 50%ADC: 50%
100% ADC50/50100% AVTE
Portfolio after 10yr
$740.4K
Annual income
$219,415.56/yr
Blended yield
29.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

AVTE
Analyst Ratings
2
Buy
6
Hold
Consensus: Hold
Price Target
$13.00
+385.1% upside vs current
Range: $2.00 — $35.00
Altman Z
2.1
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVTE buys
0
ADC buys
0
No recent congressional trades found for AVTE or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVTEADC
Forward yield74.63%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$1.30M$178.9K
Annual income after 10y$358,033.82$80,797.29
Total dividends collected$1.12M$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$13.00$81.06

Year-by-year: AVTE vs ADC ($10,000, DRIP)

YearAVTE PortfolioAVTE Income/yrADC PortfolioADC Income/yrGap
1← crossover$18,163$7,462.69$10,990$580.36+$7.2KAVTE
2$32,102$12,667.52$12,301$860.26+$19.8KAVTE
3$55,273$20,924.46$14,104$1,298.62+$41.2KAVTE
4$92,813$33,671.17$16,691$2,008.16+$76.1KAVTE
5$152,151$52,841.00$20,580$3,205.09+$131.6KAVTE
6$243,759$80,956.60$26,754$5,330.02+$217.0KAVTE
7$382,036$121,213.91$37,196$9,345.14+$344.8KAVTE
8$586,325$177,546.69$56,244$17,523.09+$530.1KAVTE
9$882,029$254,661.46$94,286$35,736.21+$787.7KAVTE
10$1,301,805$358,033.82$178,949$80,797.29+$1.12MAVTE

AVTE vs ADC: Complete Analysis 2026

AVTEStock

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Full AVTE Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this AVTE vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVTE vs SCHDAVTE vs JEPIAVTE vs OAVTE vs KOAVTE vs MAINAVTE vs NNNAVTE vs EPRTAVTE vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.